CCG-4986

• Description:

  CCG-4986 is an RGS protein inhibitor. CCG-4986 inhibits protein activity by covalently modifying the Cys-132 site of RGS4. CCG-4986 can be used to study diseases related to dysregulated G protein-coupled receptor (GPCR) signaling, such as Parkinson's disease and opioid addiction[1].

• UNSPSC:

  12352005

• Hazard Statement:

  H319

• Target:

  RGS Protein

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein

• Applications:

  Neuroscience-Neurodegeneration

• Field of Research:

  Neurological Disease; Others

• Assay Protocol:

  https://www.medchemexpress.com/ccg-4986.html

• Smiles:

  O=[N+](C1=CC=C(/S(OC)=N\S(=O)(C2=CC=C(Cl)C=C2)=O)C=C1)[O-]

• Molecular Formula:

  C13H11ClN2O5S2

• Molecular Weight:

  374.82

• Precautions:

  P264-P280-P305+P351+P338

• References & Citations:

  [1]Kimple AJ, et al. The RGS protein inhibitor CCG-4986 is a covalent modifier of the RGS4 Galpha-interaction face. Biochim Biophys Acta. 2007 Sep;1774 (9) :1213-20.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  RGS4

• CAS Number:

  [7134-19-2]